| Ticker Symbol: | NTII |
|---|---|
| Exchange: | NASD |
| Contact Info: | 2000 Powell Street Emeryville CA 94608 510 595-6000 |
| CEO/President: | Paul E. Frieman |
| Industry: | Medical - Drugs / Standard Industry Code: 2836 |
| Description: | Neurobiological Tech. is an emerging drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The company\'s strategy is to in-license and develop early-stage drug candidates that target major medical needs and which can be rapidly commercialized. |
| Shares Outstanding: | 26,910 (000) | Market Value: | 12,650 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 68.84% | Number of Inst.Shareholders: | 0.34% |
| Last Quarter Sales: | 3.51 ($Mil.) | Last Quarter Net Income: | -3.45 ($Mil.) |
| Last Quarter EPS: | -0.13 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -0.87 | |
| Most Recent Split: | 1-7 on 09/17/07 | Annual Dividend Rate: | 0 |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |